Proteins and Peptides

15 July 2015

Cerenis Therapeutics Announces the Results of the LOCATION Study

14 July 2015

Scioderm to Submit Rolling NDA to U.S. FDA for ZorblisaTM

14 July 2015

Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation

14 July 2015

Allegro Ophthalmics Announces Positive Topline Results from Phase 2 Trial Evaluating Luminate® in Patients with Vitreomacular Traction or Vitreomacular Adhesion

13 July 2015

Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes

10 July 2015

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults

10 July 2015

Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo

7 July 2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury

6 July 2015

Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

30 June 2015

CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform

30 June 2015

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

30 June 2015

Susavion Biosciences Discovers A Novel Type of Checkpoint Inhibitor

29 June 2015

CSL Behring Receives Positive CHMP Opinion for Respreeza® (human alpha-1 proteinase inhibitor) as Maintenance Treatment for Patients with Severe Alpha-1 Antitrypsin Deficiency in Europe

27 June 2015

Aratana Therapeutics Announces Positive Pivotal Results for AT-002

26 June 2015

Levemir® receives positive CHMP opinion for extended use in children as young as one year old

26 June 2015

Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

26 June 2015

Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy

25 June 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

24 June 2015

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results From Its Factor IX and Factor Xa Programs

24 June 2015

In a Phase 3 Trial, Novoeight®(Antihemophilic Factor [Recombinant]) Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Hemophilia A

24 June 2015

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

23 June 2015

Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia

23 June 2015

Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation

22 June 2015

Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A™ Study Demonstrating that Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaban)

19 June 2015

Baxalta Demonstrates Commitment to Innovation in Hemophilia and Blood Disorders at ISTH 2015 Congress

19 June 2015

Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg

18 June 2015

Admune Announces the First-in-Human Study of Heterodimeric IL-15 (hetIL-15) with Broad Applications for Cancer Immunotherapy

18 June 2015

Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program

18 June 2015

Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results

18 June 2015

Viventia Presents Validating Evidence for Highly Differentiated De-immunized Payload for Oncology at 13th Empowered Antibodies Conference

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TL1A Inhibitor Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Aflibercept (Eylea) Biosimilars Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis